Pyridone A2R Antagonists for Selective Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current modulators of adenosine receptors are nonselective, leading to adverse effects in treatments, and there is a need for subtype selective adenosine receptor agonists and antagonists to effectively manage various diseases and disorders mediated by adenosine A2A and A2B receptors.
Innovation Solution
Development of compounds that selectively modulate the adenosine A2A and A2B receptors, including their synthesis and pharmaceutical compositions, to inhibit these receptors and potentially affect adenylyl cyclase activity, offering therapeutic benefits in cancer and immune-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If nonselective adenosine receptor modulators are used, then broad receptor coverage is achieved, but adverse effects increase due to lack of subtype selectivity
Solution Approach 1:
The patent segments the adenosine receptor modulator market into subtype-specific agents, developing compounds that selectively target A2A or A2B receptors rather than acting on all adenosine receptor subtypes. This segmentation allows for tailored therapeutic effects while minimizing off-target adverse effects associated with nonselective modulators.
Solution Approach 2:
The patent applies local quality by designing molecules with specific structural features that confer selectivity for particular adenosine receptor subtypes. By modifying local molecular properties (such as substituent groups on the purine core), the compounds achieve preferential binding to A2A or A2B receptors, thereby producing localized therapeutic effects without activating other receptor subtypes that cause adverse effects.
2Object-affected harmful factors
If subtype selective adenosine receptor modulators are developed, then adverse effects are minimized, but development complexity increases
Solution Approach 1:
The patent employs parameter changes by systematically varying molecular parameters (such as substituent types, positions, and configurations on the purine core) to optimize subtype selectivity. By adjusting these chemical parameters, the development process identifies compounds with desired selectivity profiles, balancing the complexity of developing selective agents against the benefit of reduced adverse effects.
3Reliability
If selective A2A and A2B receptor modulators are used, then therapeutic efficacy for specific diseases is improved, but manufacturing complexity increases
Solution Approach 1:
The patent segments the therapeutic approach into disease-specific or condition-specific selective modulator regimens. By matching particular compounds with specific indications (e.g., A2A selectivity for Parkinson's, A2B selectivity for inflammatory conditions), the patent optimizes therapeutic efficacy for each application while streamlining manufacturing processes to focus on producing the right compound for the right indication rather than attempting universal production.
Data Source
AI summary
Compound that inhibit at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.